These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 25390744)
1. Rapid evolution of combination therapy in melanoma. Curti BD N Engl J Med; 2014 Nov; 371(20):1929-30. PubMed ID: 25390744 [No Abstract] [Full Text] [Related]
2. Skin cancer: BRAF and MEK inhibitors-good news comes in twos! Killock D Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25331181 [No Abstract] [Full Text] [Related]
3. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Daud A; Tsai K Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719 [TBL] [Abstract][Full Text] [Related]
4. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439 [TBL] [Abstract][Full Text] [Related]
5. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Erfan G; Puig S; Carrera C; Arance A; Gaba L; Victoria I; Garcia-Herrera A; Alos L; Malvehy J Acta Derm Venereol; 2017 Feb; 97(2):258-260. PubMed ID: 27353949 [No Abstract] [Full Text] [Related]
6. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. Ibrahim T; Routier E; Weill A; Baz M; Robert C Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770 [No Abstract] [Full Text] [Related]
7. MAP-kinase pathway up or down? Just look at the skin of your patients! Robert C; Thomas M; Mateus C Melanoma Res; 2014 Oct; 24(5):421-3. PubMed ID: 25185691 [No Abstract] [Full Text] [Related]
8. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib. Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754 [No Abstract] [Full Text] [Related]
9. [The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study]. Kopecký J; Kubeček O Klin Onkol; 2016; 29(2):133-8. PubMed ID: 27081804 [TBL] [Abstract][Full Text] [Related]
10. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
11. Dress syndrome secondary to different combinations of targeted therapy (iBRAF + iMEK). Robert M; Jantzem H; Etienne M; Misery L Eur J Dermatol; 2020 Jun; 30(3):303-304. PubMed ID: 32666930 [No Abstract] [Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
13. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. Melin A; Routier E; Tissot H; Rouleau E; Robert C Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065 [No Abstract] [Full Text] [Related]
14. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703 [TBL] [Abstract][Full Text] [Related]